Systemic treatment of neoplastic conditions with retinoids.
Hsu
M C
MC
Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Taipei, Taiwan, ROC.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D015474:Isotretinoin / Q000627:therapeutic use; D007641:Keratolytic Agents / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D018168:Receptors, Retinoic Acid / Q000378:metabolism; D012176:Retinoids / Q000627:therapeutic use*; D012867:Skin / Q000166:cytology / Q000187:drug effects / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy; D014212:Tretinoin / Q000627:therapeutic use
D000970:Antineoplastic Agents; D007641:Keratolytic Agents; D018168:Receptors, Retinoic Acid; D012176:Retinoids; D014212:Tretinoin; D015474:Isotretinoin